Thermo Electron Reaches the Entrepreneurial Endgame
Executive Summary
Thermo Electron is finally reversing course in its innovative, much talked about, but seldom imitated strategy of spin-offs. With almost two dozen public subsidiaries, most lacking critical mass and adequate liquidity, Thermo's new management is pulling them back in.
You may also be interested in...
Viasys Pulls Together
In under a year and a half, Viasys has transformed itself from a collection of 14 independent device companies to an integrated public company operating in four segments of the hospital market: respiratory, critical care, neurocare, and medical/surgical devices. As the successor to the companies that formerly made up the Thermo Biomedical division of Thermo Electron, it starts out with some unique challenges. It's already a public company with almost $400 million in revenues, so it has to be ever mindful of investors' expectations for growth. But it's virtually a start-up in terms of creating a corporate infrastructure and processes. Perhaps the greatest inherited weakness of Viasys is a lack of product-planning skills; Thermo Biomedical hadn't introduced a new product in seven years. Now Viasys must fill pipeline gaps with products that will appeal to its cost-conscious hospital constituency but still yield higher margins. Its middling size adds to the challenge; it's not big enough to afford a product failure, nor can it compete where financial might and product breadth are advantages. But Viasys believes it can handily apply the speed and maneuverability of a small firm to manufacture and market a large company-style product portfolio.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.